NasdaqCM:CPRXBiotechs
Angelini Interest Puts Catalyst Pharmaceuticals Rare Disease Value In Focus
Angelini Pharma is reportedly exploring a potential acquisition of Catalyst Pharmaceuticals, NasdaqCM:CPRX.
The rumors center on a possible takeover that could affect Catalyst Pharmaceuticals' valuation and control.
The news comes as Catalyst Pharmaceuticals shares last closed at $28.13.
Catalyst Pharmaceuticals has delivered strong multi year share returns, with the stock up 21.5% year to date and 15.9% over the past year. Looking further back, investors holding over three and five years...